- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Lorlatinib – November 2019
Lorlatinib: Tablet 25 mg, Tablet 100 mg; Lorviqua®
Last updated
6 March 2020